ARA-290 Research Reference

Catalog classification, reference sizes, lab math links, and source-backed data. Educational use only — not medical advice.

Researched for: innate repair receptor and neuropathy

Structural Research compound Lyophilized verified

Also known as: Cibinetide, Helix B surface peptide

Open in Calculator ← Compound Index All Tools

Quick Facts

Reference Sizes

10 mg

Storage

No approved-product storage standard exists; follow the study formulation record or lot-specific COA

Solubility

Clinical trials used study-specific aqueous IV or SC solutions; retail lyophilized material is not equivalent to the clinical formulation

Catalog Description

ARA-290, now called cibinetide, is an 11-amino-acid peptide designed from the tissue-protective surface of erythropoietin and intended to engage the innate repair receptor without stimulating erythropoiesis. Small randomized human studies used 2 mg IV three times weekly or 1, 4, and 8 mg SC daily. Surrogate nerve-fiber and symptom signals were reported, but the programs were small and do not establish broad efficacy. Cibinetide remains investigational and unapproved.

Catalog descriptions reflect research context only. Not a medical claim or treatment recommendation.

Research Profile

Half-Life

Rapid plasma clearance; a crossover PK study compared 2 mg IV with 2-6 mg SC, but a single robust terminal half-life is not consistently reported in the primary publications

Onset

Clinical and nerve-fiber endpoints were assessed over 4 weeks; acute therapeutic onset is not established

Administration Routes (Research)

IVSC

Reported Research Effects

Innate repair receptor agonism
Small randomized trials in sarcoidosis-associated small-fiber neuropathy
Corneal and epidermal nerve-fiber surrogate changes at 4 mg SC
No confirmed broad clinical efficacy

Reported Research Side Effects

Small trials reported generally acceptable short-term tolerability
Human safety database remains limited
No approved product label

Data source: Primary randomized human trials, registry results, and current market checks

Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.

Research Protocols Reported in the Literature

2 mg three times weekly [IV; 4 weeks; Monday Wednesday Friday]Source: randomized double-blind pilot study PMID 23168581
1, 4, or 8 mg daily [SC; 28 days; Once daily]Source: randomized Phase 2b study PMID 28475703

Research Notes

Current gray-market supply is overwhelmingly 10 mg lyophilized vials. Reddit reports mirror the 4 mg/day trial arm but also contain unsupported higher-dose stacks; these remain anecdotal and are not protocol evidence.

Supplementary research context only. Not medical advice or a treatment recommendation.

Sources

Safety and efficacy of ARA 290 in sarcoidosis patients with small fiber neuropathy — PubMed (NIH)
https://pubmed.ncbi.nlm.nih.gov/23168581/

Cibinetide improves corneal nerve fiber abundance in sarcoidosis-associated neuropathy — PubMed (NIH)
https://pubmed.ncbi.nlm.nih.gov/28475703/

EU trial results 2013-003016-45 — EU Clinical Trials Register
https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003016-45/results

Suggest a community source

Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.

Related Research Tools

Reconstitution CalculatorConcentration, draw volume, per-unit amounts Unit Convertermg, mcg, mL, units conversion Compound CompareSide-by-side comparison tool Cost CalculatorCost per mg, mcg, per-draw

Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.